Position in TEVA
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$18,651,719
+$4,568,752 QoQ
Shares Held
550,523
+17.7% QoQ
Ownership
0.047%
of shares outstanding
% of Portfolio
0.08%
of 13F equity value
Holder Rank
#108
of 675 holders
Holding Since
Sep 2020
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in TEVA Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Candriam S.C.A. holds $150,994,107 across 5 Drug Manufacturers - Specialty & Generic names. TEVA ranks #5 (12.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
260,926 | $43,976,468 | |
| 2 | ZTS |
Zoetis Inc.
|
474,935 | $34,128,829 | |
| 3 | UTHR |
UNITED THERAPEUTICS Corp
|
53,684 | $29,087,601 | |
| 4 | BCRX |
Biocryst Pharmaceuticals Inc
|
2,514,949 | $25,149,490 | |
| 5 | TEVA |
Teva Pharmaceutical Industries Ltd
This page
|
550,523 | $18,651,719 |
All Filings in TEVA
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $18,651,719 | 550,523 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $14,082,967 | 467,562 | Shares | Sole | 2026-04-30 | |
| 2020-09-30 | $19,371 | 2,150 | Principal | Sole | 2020-10-19 | |
| No filing history on record for this holder in this stock. | ||||||